Shameze Rampertab - Zomedica Pharmaceuticals CEO

ZOM Stock  USD 0.15  0.01  7.14%   

CEO

Mr. Shameze Rampertab is Chief Financial Officer, Executive Member of the Company. He is a seasoned financial leader in the healthcare sector with 20 years of experience, Shameze is a master of capital markets, strategic planning and financial analysis. Over the course of his distinctive and accomplished career, he successfully served as chief financial officer for multiple publicly traded healthcare startups, worked as an investment banker, thrived as a sellside healthequity research analyst, and raised over 480 million of private and public capital. Before joining Zomedica, Shameze served as CFO and secretary at Profound Medical Corporationration where he spearheaded a Qualifying Transaction with a Capital Pool Corporation resulting in the listing of shares on the TSX Venture Exchange. Prior to that, he was CFO and Vice President of Finance for Intellipharmaceutics International Inc., a NADSAQ and TSX listed pharmaceutical company. He received his chartered professional accountant and chartered accountant designations from the Canadian Institute of Chartered Accountants after earning his MBA from McMaster University and BS in molecular genetics and molecular biology from the University of Toronto. since 2020.
Age 52
Tenure 4 years
Professional MarksCPA
Address 100 Phoenix Drive, Ann Arbor, MI, United States, 48108
Phone734 369 2555
Webhttps://www.zomedica.com

Shameze Rampertab Latest Insider Activity

Tracking and analyzing the buying and selling activities of Shameze Rampertab against Zomedica Pharmaceuticals stock is an integral part of due diligence when investing in Zomedica Pharmaceuticals. Shameze Rampertab insider activity provides valuable insight into whether Zomedica Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Zomedica Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Zomedica Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
 
Shameze Rampertab over a week ago
Insider Trading

Zomedica Pharmaceuticals Management Efficiency

The company has Return on Asset of (0.0568) % which means that on every $100 spent on assets, it lost $0.0568. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.0564) %, meaning that it generated no profit with money invested by stockholders. Zomedica Pharmaceuticals' management efficiency ratios could be used to measure how well Zomedica Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 29th of March 2024, Return On Capital Employed is likely to drop to -0.08. In addition to that, Return On Assets is likely to drop to -0.06. At this time, Zomedica Pharmaceuticals' Intangible Assets are very stable compared to the past year.
The company has 1.74 M in debt with debt to equity (D/E) ratio of 0.01, which may show that the company is not taking advantage of profits from borrowing. Zomedica Pharmaceuticals has a current ratio of 42.63, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist Zomedica Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Zomedica Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Zomedica Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Zomedica to invest in growth at high rates of return. When we think about Zomedica Pharmaceuticals' use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 5 records

CEO Age

Craig MonaghanAsbury Automotive Group
59
Timothy BreenGenuine Parts Co
56
Carlos BritoAnheuser Busch Inbev
60
Brendan WhitworthAnheuser Busch Inbev
45
David HultAsbury Automotive Group
58
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan. Zomedica Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on AMEX Exchange. It employs 47 people. Zomedica Pharmaceuticals Corp (ZOM) is traded on NYSE MKT Exchange in USA. It is located in 100 Phoenix Drive, Ann Arbor, MI, United States, 48108 and employs 85 people. Zomedica Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Zomedica Pharmaceuticals Leadership Team

Elected by the shareholders, the Zomedica Pharmaceuticals' board of directors comprises two types of representatives: Zomedica Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Zomedica. The board's role is to monitor Zomedica Pharmaceuticals' management team and ensure that shareholders' interests are well served. Zomedica Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Zomedica Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Thomas Robitaille, Independent Director
Robert DiMarzo, Consultant
Jeff Rowe, Independent Member
Rodney Williams, Independent Member
Robert Cohen, Interim Chief Executive Officer, Director
Evan Peter, VP Innovation
Tom Robitaille, Independent Director
Ann Cotter, Interim Chief Financial Officer, Corporate Secretary
MBA BSBA, Chief Officer
Johnny Powers, Independent Director
Adrian Lock, GM VP
Jane Eagleson, Independent Director
Angy Guerrant, Director of Portfolio Management
Ann CPA, Chief Officer
Shameze Rampertab, Interim Chief Executive Officer, Chief Financial Officer, Executive Director
Nicole Westfall, VP Marketing
Jeffrey Rowe, Chairman of the Board
Christopher MacLeod, Independent Director
Evan MBA, Vice Innovation
Larry II, CEO President
Gerald Solensky, Executive Chairman of the Board, President, Chief Executive Officer
DVM DVM, Consultant
Anthony Blair, Chief Officer
Kristin Domanski, Vice Resources
Angie Moricz, Executive Administrative Assistant
Nicole MBA, Senior Marketing
Karen JD, Chief Secretary
Greg Blair, Senior Planning
James LeBar, Independent Member
Russell Klass, Senior Sales
William MacArthur, Executive Member and Chief Medical Officer, Director of Research and Development
Stephanie Morley, President, Chief Operating Officer
Christopher Wolfenberg, Director
Andrea Eberle, Senior Marketing Manager
Bruk Herbst, Chief Commercial Officer

Zomedica Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Zomedica Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Zomedica Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Zomedica Pharmaceuticals' short interest history, or implied volatility extrapolated from Zomedica Pharmaceuticals options trading.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Zomedica Pharmaceuticals is a strong investment it is important to analyze Zomedica Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zomedica Pharmaceuticals' future performance. For an informed investment choice regarding Zomedica Stock, refer to the following important reports:
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zomedica Pharmaceuticals Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons.
You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Complementary Tools for Zomedica Stock analysis

When running Zomedica Pharmaceuticals' price analysis, check to measure Zomedica Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zomedica Pharmaceuticals is operating at the current time. Most of Zomedica Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Zomedica Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zomedica Pharmaceuticals' price. Additionally, you may evaluate how the addition of Zomedica Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Is Zomedica Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zomedica Pharmaceuticals. If investors know Zomedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zomedica Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.02)
Revenue Per Share
0.024
Quarterly Revenue Growth
0.329
Return On Assets
(0.06)
Return On Equity
(0.06)
The market value of Zomedica Pharmaceuticals is measured differently than its book value, which is the value of Zomedica that is recorded on the company's balance sheet. Investors also form their own opinion of Zomedica Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zomedica Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zomedica Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zomedica Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zomedica Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zomedica Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zomedica Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.